



Performance of the fixed pressure valve with 
antisiphon device SPHERA® in the treatment 
of normal pressure hydrocephalus and 
prevention of overdrainage
Efeito da válvula de pressão fixa com antisifão SPHERA® no tratamento da hidrocefalia de 
pressão normal e prevenção de hiperdrenagem
Renan M. Pereira1, Mariane T. Suguimoto1, Matheus F. Oliveira2, Juliana B. Tornai3, Ricardo A. Amaral4, 
Manoel Jacobsen Teixeira3,5, Fernando Campos Gomes Pinto3
Normal pressure hydrocephalus (NPH) is a neurological 
syndrome which manifests typically between 60 and 80 years 
of age, characterized by a triad of symptoms consisting of gait 
apraxia, dementia and urinary incontinence, associated with 
ventriculomegaly (detected radiologically) and normal pres-
sure of the cerebrospinal fluid (CSF)1,2,3.
NPH can be divided into two categories: idiopathic and 
secondary. The secondary NPH occurs in the context of 
neurological events such as subarachnoid hemorrhage 
(SAH), intraventricular hemorrhage caused by trauma or 
aneurysm rupture and meningitis. In contrast, idiopathic 
NPH usually occurs between the sixth and eighth decades 
1Universidade Anhembi Morumbi, Sao Paulo SP, Brazil; 
2Hospital do Servidor Público Estadual de São Paulo, Departamento de Neurocirurgia, Sao Paulo SP, Brazil;
3Universidade de São Paulo, Hospital das Clínicas, Instituto de Psiquiatria, Divisão de Neurocirurgia Funcional, Grupo de Hidrodinâmica Cerebral, Sao Paulo SP, Brazil;
4Universidade de São Paulo, Hospital das Clínicas, Instituto de Psiquiatria, Grupo de Estudos sobre Álcool e Drogas, Sao Paulo SP, Brazil;
5Universidade de São Paulo, Faculdade de Medicina, Departamento de Neurologia,  Sao Paulo SP, Brazil;
Correpondence: Matheus Fernandes de Oliveira; Rua Loefgren, 700 / apto 103; 04040-000 São Paulo SP, Brasil; E-mail :  mafernoliv@yahoo.com.br
Conflict of interest: There is no conflict of interest to declare.
Authors declare that SPHERA® valves applied in the study were legally donated by HPBio company – São Paulo, in accordance with ethics committee of 
Hospital das Clinicas, Faculdade de Medicina da Universidade de São Paulo (CAPPESQ 10992).
Received 08 June 2015; Received in final form 15 September 2015; Accepted 05 October 2015.
AbStRACt
Normal pressure hydrocephalus (NPH) is characterized by the triad of gait apraxia, dementia and urinary incontinence associated with 
ventriculomegaly and normal pressure of  cerebrospinal fluid. Treatment is accomplished through the implantation of a ventricular shunt 
(VPS), however some complications are still frequent, like overdrainage due to siphon effect. This study analyses the performance of a valve 
with anti-siphon device (SPHERA®) in the treatment of patients with NPH and compares it with another group of patients with NPH who 
underwent the same procedure without anti-siphon mechanism (PS Medical® valve). 30 patients were consecutively enrolled in two groups 
with 15 patients each and followed clinically and radiologically for 1 year. Patients submitted to VPS with SPHERA® valve had the same 
clinical improvement as patients submitted to VPS with PS Medical®. However, complications and symptomatology due to overdrainage 
were significantly lower in SPHERA® group, suggesting it as a safe tool to treat NPH.
Keywords: normal pressure hydrocephalus, cerebrospinal fluid shunt technology, complications.
RESumo
A hidrocefalia de pressão normal (HPN) é caracterizada pela tríade de sintomas  de apraxia de marcha, demência e incontinência urinária. O tratamento 
padrão é realizado através de implantação de derivação ventricular, porém várias complicações são frequentes, como a hiperdrenagem secundária 
ao efeito sifão. Este estudo avaliou o resultado da válvula SPHERA® no tratamento desses pacientes em comparação com um grupo controle (PS 
Medical®).  30 pacientes foram consecutivamente alocados em dois grupos de 15 e seguidos por 1 ano.  Pacientes com a válvula SPHERA® tiveram 
o mesmo grau de melhora clínica em comparação ao grupo controle, no entanto as complicações diagnósticadas e sintomatologia secundária à 
hiperdrenagem foi significativamente inferior no grupo da válvula SPHERA® group, sugerindo-a como uma ferramenta segura e aplicável.
Palavras-chave: hidrocefalia de pressão normal, derivações liquóricas, complicações.
56 Arq Neuropsiquiatr 2016;74(1):55-61
of life and does not have its pathophysiological mecha-
nisms completely understood4,5,6.
Once NPH is a rare case of reversible dementia, it is es-
sential to have an adequate clinical assessment, early 
diagnosis and proper treatment in such cases 4-7. Standard 
treatment is accomplished through the implantation of 
a ventricular shunt, offering the possibility of significant 
neurological improvement7,8,9.
Different types of ventricular shunts are possible, but 
the most common is the ventricular peritoneal shunt (VPS), 
performed by using a thin catheter whose interior flow is unidi-
rectional (craniocaudal) due to the presence of a device coupled 
to the valve system, which communicates the cerebral ventricles 
with the peritoneal cavity, where the excess CSF is drained4,5,6,7.
Complications related to VPS procedure are mainly biological 
and mechanical, and the infection is still the most feared figure in 
the case of biological complications. Among mechanical compli-
cations (such as proximal shunt obstruction, headache, dizziness, 
slit ventricle syndrome, subdural or extradural hematomas, sec-
ondary paralysis of cranial nerves and craniosynostosis), the most 
frequent and important are attributed to changes related to the 
strength of drainage system, which results in excessive CSF drain-
age. This phenomenon is called siphon effect10,11,12,13,14.
In general, the siphon effect occurs due to the increased 
flow of CSF from the ventricles drained after postural chang-
es such as sit or stand up. This phenomenon is due to the 
increased hydrostatic pressure (HP) and perfusion pressure 
(PP) of the drainage system. However, there are reports in the 
literature that some physiological mechanisms, such as in-
creased intra-abdominal pressure (IAP ) and the reduction 
of intracranial pressure (ICP) during postural changes has a 
preventive effect on the siphon effect10,11,12,13,14,15,16.
Many of CSF drainage systems have been designed to pre-
vent excessive drainage such as adjustable valves, flow-regulated 
valves and gravitational antisiphon valves (the latter two valves 
not only controlled by differential pressure, but also under the 
influence of gravity as the position the body)17,18,19,20,21,22,23.
This study aims to evaluate the performance of a valve 
with anti-siphon device (SPHERA® - Figure 1)20 in the treat-
ment of patients with NPH and compare it with the perfor-
mance observed in another group of patients with NPH who 
underwent the same procedure (VPS), but whose valves had 
no anti-siphon mechanism.
mEtHoD
The research project was approved by the ethics com-
mittee of Hospital das Clinicas, Faculdade de Medicina da 
Universidade de São Paulo (CAPPESQ 10992).
Sample
Eighty nine patients with normal pressure hydrocephalus 
were selected and had their medical profiles retrospectively 
analysed. Patients presented with clinical (dementia, urinary 
incontinence, gait apraxia) and radiological (cranial tomog-
raphy or magnetic resonance imaging demonstrating ven-
triculomegaly; Evans index > 0.3). They were admitted in the 
group of Cerebral Hydrodynamics, Division of Functional 
Neurosurgery, Institute of Psychiatry, Hospital das Clinicas, 
Faculty of Medicine, University of São Paulo (HC - USP), from 
September 2008 to July 2012, treated by ventriculoperitoneal 
shunt (VPS).
Inclusion criteria were: age between 60 and 95 years old, 
clinical and radiological diagnosis of normal pressure hydro-
cephalus and improvement after lumbar puncture (Tap test).
Exclusion criteria were: presence of severe systemic diseases.
Procedures
Selection of patients
All patients were selected after clinical and radiological 
evaluation. The radiological criterion used to evaluate ven-
tricular size was the ratio of Evans, which is the ratio between 
the maximum width of the anterior horn of the lateral ven-
tricles and the maximum width of the skull (internal board 
of the parietal bones). Hydrocephalus is defined by an index 
greater than or equal to 0.3 index.
After confirming the diagnosis of normal pressure hydro-
cephalus, patients underwent a Tap test, whose steps were 
as follows:
1) The patient was analyzed according to gait and cogni-
tive pattern;
2) Then, a lumbar puncture was performed with removal 
of approximately 40-50 ml of cerebrospinal fluid (CSF);
3) After about 180 minutes, the patient was again ana-
lyzed according to gait and cognitive pattern.
From 89 patients initially selected, only 34 presented 
with improvement after Tap test, being then included in 
the study. Four patients among the 34 presented with se-
vere systemic diseases, being then excluded from study. After 
all, 30 patients participated, being consecutively divided in 
group 1 (anti-siphon) and group 2 (without anti-siphon), both 
groups with 15 patients. Allocation was performed consecu-
tively, without randomization.
Figure 1. SPHERA® Valve.
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Ventricular shunt
One group was selected for the implantation of fixed pres-
sure (medium and low pressure) with anti-siphon mechanism 
membrane (SPHERA®, HPBIO, São Paulo, Brazil) valve. SPHERA® 
valve operates by a mechanism coupled with a coil spring and a 
ruby ball (ball and spring mechanism). According to the char-
acteristic of the spring, four levels of pressure difference ensures 
a physiological flow of CSF: extra low (1 to 3 cm H2O) and low 
(3 cm H2O -7), medium (7 to 11 cm H2O) and high (11 to 14 cm 
H2O). The body of the prosthesis measures 42 x 14 x 6.5 mm. 
Its proximal portion contains the valve mechanism, the central 
part is the digital camera for pumping and punch, and the dis-
tal part contains the anti-siphon mechanism membrane. When 
the distal pressure becomes negative, the membrane temporar-
ily occludes the system, avoiding excessive drainage. This occurs 
when the patient is in the standing position (up to - 50 cm H2O) 
or additionally during inspiration in patients with ventriculo-
pleural shunt (up to - 8 cm H2O).
The other group was subjected to similar procedures, but 
without anti-siphon mechanism (PS Medical® valve, Medtronic).
The criterion for the choice of opening pressure of the im-
planted valves was the final value of CSF pressure measured after 
completion of the Tap test. Low pressure valves were implanted 
in patients who had values lower  than 4 cm H2O, medium pres-
sure in patients with values  between 5 and 10 cm H2O and high 
pressure in patients with values  greater than 10 cm H2O.
Postoperative follow-up
Patients were evaluated for a year after surgery, accord-
ing to pre-established routine outpatient visits: 10 days after 
surgery to removal of stitches, three months, six months and 
one year after surgery. Follow-up criteria were:
• Clinical: comparison of pre and post neurological surgery, 
presence of signs and symptoms of malfunction or excessive 
drainage system (headache, positional headaches, nausea, 
vomiting, visual changes, altered level of consciousness);
• Radiological: pre and postoperative CT, immediately after 
surgery and after three months. Signs of CSF hypodrainage 
(Evans index > 0.3) and signs of CSF overdrainage (subdural 
collections > 1 cm) were evaluated.
Scales
The following scales were used for clinical and radiologi-
cal assessment of the patients:
1) Mini Mental State Examination (MMSE)21,22
Objective: To evaluate cognitive changes.
Score: 0 to 30 (higher is better).
2) Japanese NPH Scale (NPH Scale)23 – Figure 2
Objective: scoring patients according to clinical charac-
teristics of NPH triad.
Score: 0 to 12 (higher is worse).
Statistics
According to the nature of the variables the data were 
analyzed by the absolute and relative frequency and ap-
plied the following tests: Kolmogorov-Smirnov test, t-test, 
Mann-Whitney and Wilcoxon. The value of 5% (p < 0.05) was 
adopted as the threshold for rejecting the null hypothesis 
with a confidence interval of 95%.
RESuLtS
Anthropometric data
Of the 30 patients, there were 23 men and 7 wom-
en. In group 1 (SPHERA®), age ranged from 60 to 85 years 
(mean 71 years) and Body Mass Index (BMI) ranged from 18 
to 30 kg/m2 (mean 24.8 kg/m2 ). In group 2 (PS Medical®), age 
ranged between 60-79 years (mean 70 years) and BMI ranged 
from 21 to 36.8 kg/m2 (mean 26 kg/m2 ). There was no statisti-
cal difference between the mean age and BMI between groups.
Twenty-five patients had complete clinical triad, 2 patients 
had gait apraxia and urinary incontinence, 2 patients had gait 
apraxia and dementia and 1 patient had only dementia. All pa-
tients had communicating hydrocephalus according to CT and 
MRI, and Evans index ranged from 30% to 49% (mean 39.8%).
Table 1 shows the scores obtained by using the Japanese 
scale for NPH while performing Tap-test, after 3 months and 
12 months after surgery.
Figure 2. Japanese scale for NPH.
Table 1. Normal pressure hydrocephalus (NPH) Japanese scale during Tap test and follow-up.
Group Best before Tap test Best after Tap test After 3 months After 12 months
Group 1 – anti-siphon (n = 15)
NPH scale 8 (5-12) 7 (2-12) 8 (4-12) 6 (1-12)
Group 2 – without anti-siphon (n = 15)
NPH scale 6 (2-11) 5 (2-8) 4 (0-10) 6 (0-12)
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Group 1 (SPHERA® valve)
Of the 15 patients who constituted group 1, 12 were men 
and 3 were women. Medium pressure valves were implanted 
in 10 patients and low pressure valves (SPHERA®, HPBIO) in 
5 patients.
Clinical evaluation
After one year of follow up, 10 patients had clinical im-
provement (10/15 = 66%), 2 patients (2/15 = 13%) remained 
unchanged compared to the preoperative period and 
3 patients (3/15 = 20%) showed clinical worsening after one 
year of monitoring. During cognitive assessment by MMSE, 
the best results (mean and variation) before and after the Tap 
test, after 3 months and after 1 year were 14 (8-22), 14 (2-23), 
14 (3-26) and 15 (9-27), respectively.
Radiological evaluation
Eleven patients showed no signs of parenchymal bleeding 
or subdural collections after one year of surgery (Figure 3). 
Two patients presented 45 days and 6 months after surgery 
subdural chronic hematomas in the right cerebral hemi-
sphere, both in the right frontoparietal region. In the first 
case, there was 2 cm in the greatest thickness. In the second 
case, it was observed thickness of 1.5 cm and minimum de-
viation from the midline to the left. In both cases there was 
need for surgical drainage without changing valves.
Table 2 shows the radiographic patterns presented by pa-
tients in group 1.
Group 2 (PS medical® valve)
Of the 15 patients who constituted group 2, 11 were men 
and 4 were women. 12 medium pressure valves and 3 low 
pressure valves (PS Medical®, Medtronic) were implanted.
Clinical evaluation
After one year of follow-up, 8 patients (8/15  =  53%) 
showed clinical improvement, 2 patients (2/15  =  13%) 
remained unchanged compared to the preoperative period 
and 5 patients (5/ 15 = 33%) showed clinical worsening after 
a year of monitoring.
During cognitive assessment by MMSE, the best results 
(mean and variation) before and after the Tap test, after 3 
months and after 1 year were 22 (13-29), 20 (1-30), 16 (2-29) 
and 21 (10-30), respectively.
Radiological evaluation
Five patients had chronic subdural hematoma > 1 cm dur-
ing follow-up (Figure 4). One in the first month ( frontoparietal 
region, measuring 2.1 cm; two after two months (both right 
frontoparietal region without midline deviation or ventricular 
compression, one measuring 1.2 cm, and the other measuring 
1.4 cm); one after three months (in the right frontal parietal 
region measuring 1.1 cm without midline deviation or ventric-
ular compression) and one six months after surgery (bilateral 
frontoparietal region, measuring 1.2 cm).
Four of the five largest hematomas that occurred in the 
first six months required reoperations for hematoma evacu-
ation and replace valves for high-pressure valves (three cases 
after 2 months of surgery) and closure of the shunt system 
by occlusion of catheter (one patient 3 months after surgery). 
The remaining case was approached conservatively.
One patient had slit ventricles syndrome after six months 
of surgery without midline deviation or ventricular compres-
sion (Figure 5). We opted for a conservative approach.
Table 3 presents the radiographic patterns presented by 
patients in group 2.
Comparison between groups
In both groups, there was clinical improvement after one 
year (p = 0.005) and that was superior in Group 1, however 
without statistical significance (p  =  0.059). NPH scale after 
one year revealed statistical significant difference in both 
groups (p = 0.005), while Evans index did not differ in both 
groups (p = 0.105).
Overdrainage complications were significantly lower in 
Group 1 (p = 0.042). The need for reoperation in the first year 
after surgery in both groups is presented in Table 4. There 
was a smaller number of reoperations in Group 1, not statisti-
cally significant (p > 0.05).
Table 5 presents the causes of emergency room care in 
the HCFMUSP during the first year after surgery of patients 
in groups 1 and 2. There were fewer clinical complications in 
group 1 (p = 0.05).
Figure 3. Pre and post operative images of a typical normal 
pressure hydrocephalus patient of group 1.
Table 2. Radiological evaluation in group 1.









1 - 1 - -
Subdural hematomas 
< 1 cm
- - - - -
Ventricular enlargement - - - 1 -
Hemoventricle - - 1 - -
Slit ventricle - - - - -
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DISCuSSIoN
Normal pressure hydrocephalus is one of the few causes 
of dementia with potential for reversal of symptoms. Hakim 
and Adams in 1965 described the classic triad that can char-
acterize disease in varying degrees of combination1,2,3.
A ventriculoperitoneal shunt is the procedure of choice 
for the treatment of NPH. Approximately 50-70% of patients 
report improvement after shunt. However, complications 
related to the procedure are still frequent and often severe, 
ranging from 13 to 40% of patients in the main series. The 
siphon effect, which occurs due to the increased flow of 
CSF from the ventricles drained after postural changes, like 
sit or stand, is being increasingly investigated in order to 
reduce complications4,5,6,7,8,9,10.
Many CSF drainage systems have been designed to prevent 
excessive drainage such as adjustable valves, flow-regulated 
valves, and gravitational anti-siphon valves24,25.
Several studies are known in this regard. The Codman 
Medos valve, for example, allows adjustment of the pres-
sure in 18 levels between 30 and 200 mm H2O. A series of 
90 patients was published with satisfactory clinical results. 
Another retrospective study was published in 583 patients 
with hydrocephalus due to various causes who were treated 
with the Codman Hakim programmable valve. The proGAV 
valve (Aesculap) also has support in the literature26,27.
The use of Strata® valve has been described previously, 
with a success rate of approximately 80% and 20% of 
Figure 5. Pre and post operative images of a subject of group 2 who developed slit ventricle syndrome after ventricular peritoneal shunt.
Figure 4. Pre and post operative images of a subject of group 2 who developed subdural hematoma after ventricular peritoneal shunt.
Table 3. Radiological evaluation in group 2.












- - 2 - -
Ventricular enlargement - 2 1 -
Hemoventricle - - - -
Slit ventricle - - 1 - -
Table 4. Reoperation after 1 year.
3 ms 6 months 9 months 12 months
Group 1 1 - 1 -
Group 2 4 - - -
Table 5. Reasons for emergencial medical evaluation during 
the first year after surgery in groups 1 and 2.




Impairment of level of consciousness 1 5
Dizziness 1 3
Falls 1 2
Behavior changes 2 3
Vomiting 1 2
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complications28,29,30. Orbis Sigma® is a self-regulating valve 
and constant flow valve. Despite being probably one tool ap-
plicable in cases of NPH, the literature lacks studies corrobo-
rating results in these patients31.
Once complications related to CSF overdrainage are fre-
quent and may be severe, the present study evaluated the 
performance of a valve with anti-siphon device (SPHERA®) 
in the treatment of patients with NPH compared to the per-
formance observed in another group of patients with NPH 
who underwent the same procedure, but whose valves had 
no anti-siphon mechanism (PS Medical®, Medtronic).
We evaluated 30 patients with NPH separated into 2 
groups according to the type of valve used. We studied 
the clinical and radiological outcome, complications, re-
operations, and symptomatology after a 1 year follow up. 
In group 1 (Anti-siphon), the improvement rate was 66 %, 
with 5 radiological complications and reoperation in 2 
patients. In group 2 (without Anti-siphon), there was im-
provement in 53% of patients, with 11 complications and 
reoperation in 3 patients.
In both groups, there was clinical improvement after one 
year (p = 0.005) and that was superior in group 1, however 
without statistical significance (p  =  0.059). Overdrainage 
complications were significantly lower in group 1 (p = 0.042). 
There was a smaller number of reoperations in group 1, not 
statistically significant (p  >  0.05). Thus, SPHERA® valve was 
similar to the fixed pressure valve PS Medical® regarding 
clinical treatment and was superior in the management of 
overdrainage complications.
The use of valves with different pressures between the 
two groups (low and medium) were statistically signifi-
cant (p = 0.025). Then a regression analysis was performed 
by controlling this variable. With this control, the variable 
“had complication” was significantly different between 
groups (p = 0.049).
As there were more patients in group 2 with medium 
pressure valves than in group 1, it was expected that the 
first presented with lower rates of overdrainage. However, in 
reality, a larger number of overdrainage complications hap-
pened in group 2, reinforcing the role of Anti-siphon device of 
SPHERA® valve in preventing such complications.
Some limitations should be considered. First, our anal-
ysis was a retrospective study without randomization in 
group allocation. The best study design to test hypothesis 
should be prospective and randomized. This methodologi-
cal weakness surely brings bias which may interfere with 
inferences from study.
Additionally, when the patient is elderly, one should be 
cautious with the results of improvement of dementia after 
shunt. The association with Alzheimer’s disease and other 
dementia is known, sometimes without any improvement 
after shunt32.
Then, we did not use any objective functional scale to as-
sess patients, such as the modified Rankin Scale and Barthel 
Index. Additionally, screening for shunt surgery was based on 
the results of Tap test. It was the only preoperative test used 
for the treatment of patients due to its applicability, validi-
ty and availability, as well as patient comfort, because hos-
pitalization was not required during the protocol. Although 
with lower sensitivity (26-61%) compared to the infusion test 
(57-100%) and external lumbar drainage (50-100%), Tap test 
is feasible and its only great weakness is the potential loss of 
candidates for surgery30.
Another important point is that the gold standard 
treatment for NPH is currently done with programmable 
valves9,20. Thus, comparison of SPHERA® valve with a type 
of fixed pressure valve (PS Medical®) may decrease, but 
not invalidate the superiority of SPHERA® valve. Future tri-
als comparing the latter with programmable valves will be 
needed to clarify these questions.
A linear relationship between shunt valve type and 
incidence of subdural hematoma remains unclear. 
Although there is limited evidence data generally assum-
ing that subdural hematoma formation may occur as a 
consequence of excessive or too rapid CSF drainage, the 
use of flow-limiting valves or antisiphon devices to re-
duce the incidence of subdural hematomas has yet to be 
clearly proved.
We must highlight that SPHERA® valves applied in the 
study were donated by HPBio company. Finally, our results 
are tied to a 1-year follow-up. Although encouraging, they are 
still initial and further follow up must be documented.
In conclusion, SPHERA® valve showed satisfactory results, 
since the clinical improvement was observed in 66% of pa-
tients and complications were significantly less common be-
cause of Anti-siphon device.
Certainly, further studies are needed. However, 
SPHERA® valve is a safe and applicable tool in the 
treatment of NPH.
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